24 May, 2021

2021 AACR: Longitudinal Exome-Scale Liquid Biopsy Monitoring of Evolving Therapeutic Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma Patients Receiving Anti-PD-1 Therapy

2021 AACR: Longitudinal Exome-Scale Liquid Biopsy Monitoring of Evolving Therapeutic Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma Patients Receiving Anti-PD-1 Therapy Typical liquid biopsy panels capture a relatively small number of variants, and likely under-represent the heterogeneity of resistance in late-stage cancers. To address the challenges associated with identifying multiple concurrent heterogeneous [...]

22 May, 2021

2021 AACR: Accurate modeling of antigen processing and MHC peptide presentation using large-scale immunopeptidomes and a novel machine learning framework

2021 AACR: Accurate modeling of antigen processing and MHC peptide presentation using large-scale immunopeptidomes and a novel machine learning framework Neoantigens, which are antigens specific to cancer cells, can be harnessed to develop personalized cancer vaccines and prognostic biomarkers for checkpoint blockade inhibition. Next generation sequencing technologies have enabled comprehensive profiling of putative neoantigens [...]

22 May, 2021

2021 AACR: Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS based machine learning algorithm

2021 AACR: Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS based machine learning algorithm HLA loss of heterozygosity (LOH) is increasingly being recognized as an important immune escape mechanism in response to checkpoint inhibitor therapy. HLA LOH reduces the repertoire of neoantigens displayed on the cell surface of cancer cells, [...]

22 May, 2021

2021 AACR: Pan-cancer shedding patterns of tumor circulating cell-free DNA

2021 AACR: Pan-cancer shedding patterns of tumor circulating cell-free DNA Tumor circulating cell-free DNA (ctDNA) comprises DNA molecules cast from tumors that reach and circulate in a patient's bloodstream. Given its non-invasive nature, the liquid biopsy of ctDNA has remarkable potential for diagnosis, prognosis, disease progression tracking, and treatment monitoring. Nonetheless, little is known [...]

22 May, 2021

2021 AACR: Profiling tumor-infiltrating immune cells using an augmented transcriptome

2021 AACR: Profiling tumor-infiltrating immune cells using an augmented transcriptome Due to the complexity of tumor-immune interactions, comprehensive profiling of both the tumor and tumor microenvironment (TME) can help further our understanding of tumor progression and response to treatment. One significant application is quantification of the immune infiltrate, which has the potential to characterize [...]

24 Nov, 2020

2020 SITC: Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity

2020 SITC: Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity T cells can inhibit tumor growth and progression by recognizing major histocompatibility complex class I (MHC-I) -bound peptides derived from antigens that are mutated, inappropriately expressed, or overexpressed in the tumor cells (vs. healthy cells). There are many mechanisms by which [...]

24 Nov, 2020

2020 SITC: B-cell receptor heavy chain repertoire profiling using an augmented transcriptome

2020 SITC: B-cell receptor heavy chain repertoire profiling using an augmented transcriptome Comprehensively profiling the tumor and tumor microenvironment (TME) can help provide a more complete view of the complex interactions between the tumor and immune system, potentially furthering our understanding of tumor progression and response to treatment. We have developed an augmented, immuno-oncology-optimized exome/transcriptome [...]

24 Nov, 2020

2020 SITC: Profiling tumor circulating cell-free DNA with an enhanced whole-exome to enable sensitive assessment of somatic mutations

2020 SITC: Profiling tumor circulating cell-free DNA with an enhanced whole-exome to enable sensitive assessment of somatic mutations The analysis of tumors using circulating cell-free DNA (cfDNA) is beginning to transform cancer diagnosis, prognosis, response to therapy and to enable disease progression monitoring. Most cfDNA assays are centered around the identification of therapeutically actionable [...]

24 Nov, 2020

2020 SITC: Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets

2020 SITC: Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Our ImmunoID NeXT™ Platform enables a [...]

24 Nov, 2020

2020 AMP: An exome and transcriptome based NeXT Dx™ test enables therapy selection for cancer patients and offers insight into emerging composite biomarkers for immunotherapy

2020 AMP: An exome and transcriptome based NeXT Dx™ test enables therapy selection for cancer patients and offers insight into emerging composite biomarkers for immunotherapy The emergence of immune checkpoint inhibitors has highlighted the potential of immuno-oncology therapeutics to produce unprecedented beneficial responses in cancer patients. However, diagnostic biomarkers that consistently predict patient response [...]

Go to Top